Brief Introduction

Registered to be established in Zhongguancun Life Science Park in March 2011, Novogene is specialized in the application of advanced molecular biotechnology and the high-performance computing in the life science research and human health fields. It strives to become a global leading provider of genetic science and technology product and service. The Company has established the high-flux large-scale gene sequencing and the high-performance computing platforms, which effectively support the demands of the life science research and medical health for big data analysis and storage.

As the leader in the gene sequencing field in China, Novogene's business covers the fundamental scientific research service of life science, medical research and technology service, storage-building sequencing platform service, providing gene sequencing, mass spectrometry and bio-information technology support for global research universities, scientific research institutions, hospitals, pharmaceutical R&D enterprises and agricultural enterprises.

Since its establishment, Novogene has successively obtained several qualifications and honors including National High-tech Enterprise, Scientific Research and Development Institution of Beijing City, Pilot Patent Unit of Beijing City, Enterprise Technology Center of Beijing City and Gene Detection Technology Application Demonstration Center of National Development and Reform Commission, and established Engineering Lab of Beijing City.

Novogene has established extensive cooperation with many academic institutions all over the world, and completed several genomics research projects with internationally advanced level. By October 2020, Novogene published more than 600 SCI articles in cooperation with project partners,accumulating impact factors over 4270. Currently, it has obtained 208 software copyrights and 36 patents. It has partners all over the world, including over 2,600 scientific research institutions and universities, over 590 hospitals, over 1,200 pharmaceutical and agricultural enterprises.

Headquartered in Beijing, the Company has established labs or experimental bases in Tianjin, Nanjing, UK and Singapore, and set up branches in Hong Kong China, US, UK, Singapore, Netherlands, Japan, and Thailand, with the office area exceeding 40,000m2. At present, Novogene has set up a high-quality comprehensive interdisciplinary team composed of members from top universities in China and overseas. We've proudly served over 4,000 customers all over the world, covering about 70 countries and regions in Six Continents.

Company Overview

Full name Novogene Co., Ltd.
Abbreviations Novogene
Code 688315
Founded 2011-03-15
Listing 2021-04-13
Domicile Beijing
STAR Theme Biomedicine
CSRC Sector Scientific research and technical service
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 0.10 0.32 0.27
R&D expenditure as a % of operating revenue 7.54% 8.19% 7.54%
Operating Revenue 1,490.03 1,534.83 1,053.56
Net Income 34.44 114.43 97.87

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 1,490.03 1,534.83 1,053.56
Operating Costs 966.68 933.89 601.74
Operating Income 36.07 119.27 112.90
Pretax Income 35.53 119.21 112.87
Income Tax 1.09 4.78 15.00
Net Income 34.44 114.43 97.87

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 1,201.86 1,123.59 681.06
Non-current Assets-Total 822.87 846.57 790.30
Total Assets 2,024.73 1,970.16 1,471.36
Current Liabilities-Total 897.48 872.89 486.96
Non-current Liabilities-Total 6.38 10.27 12.26
Total Liabilities 903.86 883.17 499.22
Stockholder's Equity
Share Capital 791.89 791.89 791.89
Retained Profits 324.36 290.68 175.83
Minority Interests 4.63 4.42 4.42
Total Owners' Equity 1,120.88 1,086.99 972.14

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 342.07 85.36 151.43
Net Cash Flows-Investing -73.93 -139.58 -19.41
Net Cash Flows-Financing -119.23 179.68 -51.36

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
Ruiqiang Li 214.81 59.67%
Beijing Zhiyuan HeguInvestment ManagementCenter 55.04 15.29%
成长拾贰号投资(深圳)合伙企业(有限合伙) 22.90 6.36%
Future Industry Investment Fund 18.13 5.04%
Zhi Jiang 15.73 4.37%
Beijing Nuohe HeguInvestment ManagementCenter 12.58 3.49%
红杉安辰(厦门)股权投资合伙企业(有限合伙) 9.53 2.65%
深圳市招商招银股权投资基金合伙企业(有限合伙) 3 0.83%
中集资本管理有限公司 1.8 0.5%
China Trade in Service Innovation Investment Fund 1.8 0.5%
Hai Chuang Fund of Funds 1.8 0.5%
  As of 2021-03-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.